Having trouble viewing this email? View the online version. Unsubscribe.
SexHealthMatters logo
FDA Approves Addyi to Treat Low Desire in Women

History was made last week when the U.S. Food and Drug Administration approved Addyi (flibanserin), a drug designed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.

Sprout Pharmaceuticals, the maker of Addyi, expects to have it on the market by October 17. 

Women with HSDD have no desire for or interest in sex, to the point that it causes them distress. Relationships may suffer, too. 

Addyi is the first drug of its kind. But it's not for everyone. Click here more information about the drug, the approval process, and safety concerns.

Also, keep your eyes open for our next blog post, which will answer many of your questions about Addyi. 

Fewer Men with ED are Getting Penile Implants

Developed in the 1960s, penile implants have long been a treatment option for men with erectile dysfunction (ED).  But in recent years, the popularity of implants has started to wane. 

In fact, the number of implant procedures dropped 50% among Medicare participants in the United States between 2001 and 2010. 

Rates have also varied by U.S. region and by ethnicity. For example, penile implants appear to be more common in the southern and western parts of the U.S. and in African-American men. 

Why are implant rates falling? Click here to find out. You'll also learn more about the study, the participants, and the demographics involved with implant procedures. 

Did You Know?

Erectile dysfunction (ED) is more common in men with gout. Find out why. 

Men with premature ejaculation may benefit from a painkiller called tramadol. More details.

In the News

Testosterone Guidelines Updated

Last month, the International Society for Sexual Medicine (ISSM) published new guidelines to help healthcare providers properly diagnose, treat, and manage testosterone deficiency in adult men. 

The "Process of Care" is the result of extensive research and discussions by some of the top experts in the field. 

It provides updated information for all clinicians, especially family physicians and others who do not specialize in sexual medicine, urology, or endocrinology.  

Read more here.

Experts Say ED Drugs are Unlikely to Cause Melanoma

Researchers from the United States and Europe have concluded that erectile dysfunction drugs most likely do not cause melanoma, a form of skin cancer.

Their study built on previous research that suggested a possible link between sildenafil and melanoma. 

It's possible that lifestyle factors may play a role in the higher melanoma rates among ED drug users, they explained.

Get more details here. 

You are receiving this newsletter because you are subscribed to our mailing list.
If you would rather not receive emails like this in the future you can unsubscribe.

Sexhealthmatters.org | Sexual Medicine Society of North America, Inc.
PO Box 160, Holly Ridge, NC 28445